Sunesis Pharmaceuticals (SNSS) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
Roth Affirms Sunesis (SNSS) at 'Neutral'; ASH Presentations May Help Clear Cloudy Outlook
November 11, 2014 9:12 AM ESTRoth Capital affirms its Neutral rating and $1.30 price target on Sunesis Pharma (Nasdaq: SNSS) following Q3 results. Early Monday, Sunesis reported Q3 loss of $0.25 per share, whle the firms was looking for a loss of just $0.07 per share.
Analyst Joseph Pantginis commented on the results: With the recent Phase III VALOR study not achieving its endpoint of OS, we are mindful of developments... More
